Novadiscovery
Evgueni Jacob is a biostatistician with extensive experience in the field of statistical methodology and analysis within healthcare and bioinformatics. Since September 2015, Evgueni has been employed at Nova In Silico, holding the position of Biostatisticien. Prior experience includes a role as Stagiaire Biostatisticien at Hospices Civils de Lyon, where Evgueni developed a statistical methodology to evaluate factors affecting performance in high-throughput sequencing data pipelines. Additional internships involved predictive studies of immunoglobulins in a pediatric cystic fibrosis cohort and analysis of asthma impacts on healthcare consumption in children with cystic fibrosis. Earlier experience includes an internship at the Laboratoire de Biométrie et de Biologie Evolutive, focusing on the statistical analysis of DNA sequences. Evgueni holds a Master's degree in Public Health with a specialization in Biostatistics from Université Claude Bernard Lyon 1 and a Bachelor's degree in Sciences, Technologies, and Health, also from the same institution.
Novadiscovery
novadiscovery is a developer of a drug discovery platform in silico clinical trials designed to de-risk, optimize research and development along with curbing the cost of discovering new drugs. The company's platform uses mathematics and intelligent algorithms to build a community of virtual patients as on-demand digital lab rats, enablingscientists and biotech, pharma companies to predict drug efficacy and create the target combination.